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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the eGects of chloroquine (CQ) and hydroxychloroquine (HCQ) as:
1. an antiviral treatment on death and time to clearance of the virus from clinical samples and recovery in people with COVID-19;
2. a prophylactic treatment on prevention of COVID-19 in people at risk of SARS-CoV-2 exposure;
3. a prophylactic treatment on prevention of COVID-19 in people who have been exposed to SARS-CoV-2.
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B A C K G R O U N D
Description of the condition
Coronavirus disease 2019 (COVID-19) is a viral infection transmitted
by respiratory  droplet spread and caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19
commonly presents as a mild respiratory tract illness, with fever
and cough the most commonly reported symptoms; however, in
some people, this progresses to cause a life-threatening respiratory
syndrome (Guan 2020).
SARS-CoV-2 is a novel coronavirus that has undergone widespread
transmission since December 2019. Close to 2.5 million people
have been diagnosed with COVID-19, and over 170,000 people
have died as of 21 April 2020 (JHU 2020). The World Health
Organization (WHO) declared COVID-19 a public health emergency
of international concern on 30 January 2020, and a pandemic on 11
March 2020 (WHO 2020a).
National data from China and Italy describe severe disease in
14% to 20% of people with COVID-19, and a further 2% to 5%
are reported to have critical illness (ISS 2020; Wu 2020). Mortality
estimates range from around 2% to 12% (ISS 2020; Wu 2020).
Severe disease is characterized by hypoxia and progressive acute
respiratory distress syndrome appears to be the driver for mortality,
although patients can experience a syndrome with clinical and
laboratory features of severe systemic inflammation, termed a
“cytokine storm” (Guan 2020; Mehta 2020).
At the other end of the spectrum, asymptomatic infection is not
uncommon; national Italian data describes this in approximately
10% of all people with a confirmed COVID-19 diagnosis (ISS 2020).
Transmission is by direct contact with people with the
infection,  indirectly via  contact with respiratory secretions on
objects and surfaces, or from droplets generated by sneezing and
coughing (WHO 2020b). Concerns have been raised about airborne
transmission: viability of SARS-CoV-2 has been demonstrated for at
least 3 hours when suspended in an aerosol (van Doremalen 2020).
The amount of virus found in the respiratory tract appears to be
higher in people with severe versus those with mild disease, with
shedding of virus in the nasopharynx occurring for up to 25 days
in people with severe disease (Liu 2020a). The virus has also been
found in stools, with one study reporting live virus in non-diarrhoeal
stool thus raising concerns about faecal-oral transmission (Wang
2020a).
Multiple episodes of transmission by pre-symptomatic or
asymptomatic people have been described (Bai 2020; Rothe 2020).
The main method for diagnosis of COVID-19 is by polymerase
chain reaction (PCR) of respiratory tract samples, mostly from
the nasopharynx or oropharynx. However, some guidelines advise
nasal swabs (CDC 2020), and some evidence suggests lower
respiratory samples, such as sputum, may have higher sensitivity
(Wang 2020a). While viraemia is rare, serological tests are being
developed, using either antibody or antigen detection; it is hoped
that a positive antibody test will confirm that someone has been
previously infected with SARS-CoV-2 and is now immune (Amanat
2020).
Transmission is common in, though not limited to, households
(Pung 2020). Self-isolation, quarantine, and travel restrictions can
limit community transmission (Kraemer 2020), but prevention
measures within households can be more challenging. Healthcare
workers are at high risk of being infected. Data from Italy
show that 20% of frontline healthcare workers responding to
the pandemic have developed COVID-19 (Lancet 2020). There
is widespread shortage of personal protective equipment, and
there are concerns about airborne transmission (Lewis 2020). With
established community transmission in many countries, healthcare
workers are also at risk outside of health facilities. With vaccines
entering trial stage but unlikely to report clinical data within a few
months, there is great interest in chemoprophylaxis for prevention
of COVID-19.
Several potential antivirals have been suggested for treating
people with COVID-19, with studies attempting to demonstrate
eGectiveness of the influenza treatments arbidol (Deng 2020) and
favipiravir (Cai 2020); and the antiretroviral protease inhibitor
combination lopinavir/ritonavir (Cao 2020). Remdesivir, a drug
trialled for Ebola virus disease and Middle East respiratory
syndrome (MERS), has shown promising results in vitro (Wang
2020b). Multiple trials have been set up to establish evidence
for eGectiveness of these in patients with COVID-19. Many other
options are being investigated, including corticosteroids (EudraCT
2020-001113-21), tocilizumab (Xu 2020), convalescent plasma
(Shen 2020), and camostat  mesylate (HoGman 2020). Research
groups have been using novel methods to assess whether existing
drugs can be repurposed for COVID-19 treatment (Chandel 2020;
Zhou 2020).
Description of the intervention
Chloroquine (CQ) and hydroxychloroquine (HCQ) are 4-
aminoquinoline compounds, derivatives of quinine, and have been
used as antimalarial drugs since the 1940s (Ben-Zvi 2012). HCQ
is an analogue of CQ in which one of the N-ethyl substituents of
CQ is β-hydroxylated. HCQ and CQ have similar pharmacokinetic
properties, with high oral bioavailability and tissue penetrance,
partial hepatic metabolism, and high volumes of distribution as
they diGuse into adipose tissue (Ben-Zvi 2012).
Both drugs have been used widely and for many years for treatment
and prophylaxis of malaria and treatment of rheumatological
conditions, such as systemic lupus erythematosus and rheumatoid
arthritis (Steinhardt 2011; Fiehn 2020).
The mechanism of action in the treatment and prevention
of malaria is thought to result from inhibition of the
biocrystallization of hemozoin, causing cytotoxic accumulation of
heme (Schrezenmeier 2020). For rheumatological conditions, the
mechanism of action is not fully delineated, but appears to arise
from multiple eGects. As weak bases, both CQ and HCQ accumulate
in the acidic environment within lysosomes, and thus interfere with
lysosomal activity and autophagy, which in turn may inhibit major
histocompatibility complex (MHC) class II expression and antigen
presentation, inhibiting immune activation (Schrezenmeier 2020).
CQ and HCQ also interfere with Toll-like receptor (TLR) signalling,
again via changes to local pH but also through direct binding to
nucleic acids. TLR signal pathways stimulate cytokine production,
and CQ and HCQ have been demonstrated to inhibit production of
various cytokines including interleukin (IL)-1, IL-6, tumour necrosis
factor (TNF), and interferon gamma (IFNγ) by mononuclear cells
(van den Borne 1997).
CQ and HCQ have well-described adverse eGect profiles. Common
adverse eGects include gastrointestinal upset and headache (Ben-
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Protocol)









Cochrane Database of Systematic Reviews
Zvi 2012). Several adverse eGects  are associated with
chronic therapy, such as QT interval prolongation on
electrocardiogram,  other cardiac arrhythmia, and retinopathy
(Fiehn 2020). CQ is generally less tolerable than HCQ, and can cause
acute poisoning at a lower dose, as has been seen in reports from
the USA and Nigeria of members of the public taking CQ without a
prescription (CNN 2020; Owens 2020).
There are two types of CQ salts: CQ phosphate and CQ sulphate.
Most dosing recommendations for CQ refer to the salt rather
than the base compound. Usual doses for CQ are 250 mg to 500
mg CQ phosphate  (155 mg to 310 mg CQ base) per dose, or
CQ sulphate 200 mg (150 mg CQ base), with weekly dosing for
malaria prophylaxis, and daily dosing for treatment of malaria and
rheumatological conditions. HCQ is given at a dose of 400 mg
weekly for  malaria prophylaxis, and 200 mg to 400mg daily for
rheumatological disease (Ben-Zvi 2012).
How the intervention might work
Both CQ and HCQ have been suggested as agents for treatment
and prevention of COVID-19. Studies have reported in vitro activity
against SARS-CoV-2 (Liu 2020b; Wang 2020b; Yao 2020), and
pharmacokinetic modelling suggests eGicacy of a few postulated
dosing regimens for treatment (Yao 2020).
Liu 2020b reported that CQ and HCQ appear to inhibit transport
of SARS-CoV-2 virions from early endosomes to endolysosomes in
Vero E6 cells, which may be a requirement for release of the viral
genome and subsequent viral replication. Wang 2020b performed
a "time-to-addition" assay using Vero  E6 cells, and found that
CQ appeared to both inhibit entry of SARS-CoV-2 into cells, and
inhibit viral replication aTer cell entry. The authors of both studies
also speculate that CQ and HCQ could impact on disease severity
in CoVID-19 through modulating the excess cytokine release that
appears to contribute to life-threatening forms of the disease (Liu
2020b; Wang 2020b).
Why it is important to do this review
Given the pace of the pandemic, and the extraordinary impact
on public health and society in many countries, there is high
demand for eGective prevention and treatment for COVID-19. CQ
and HCQ are cheap drugs that are registered in most countries,
and are included on the WHO essential medicines list (WHO
2019). They can be delivered orally, and both drugs have well-
described safety profiles in adults and children. Given the lack of
eGective antiviral drugs that can treat COVID-19, or an eGective
vaccine, identifying existing medicines that may be of benefit is of
high importance. Despite the small number of published studies,
some governments have already recommended using HCQ as
prophylaxis for healthcare workers, and some prominent political
figures have asserted that CQ or HCQ should be used as a first-line
treatment for COVID-19. Sadly, there have already been instances
of significant harm where individuals have misinterpreted news
stories about the use of CQ, and suGered toxicity.
Several national guidelines are recommending CQ or HCQ
for treatment of patients with COVID-19. Belgian guidelines
recommend HCQ for severe disease, and advise to consider HCQ for
mild-moderate disease (WIV-ISP 2020); Chinese guidelines advise
consideration of CQ in all hospitalized patients, although later
iterations have expressed caution regarding dosing and special
patient groups (Wong 2020); Italian guidelines recommend early
use of CQ or HCQ, or lopinavir/ritonavir (Brescia-COVID Group
2020). The WHO, the US Centers for Disease Control and Prevention
(CDC), and Public Health England are yet to recommend CQ or HCQ
for treatment.
Most guidelines cite interim results of two studies. A brief
letter on 19 February 2020 reported that a news briefing on
17 February stated that "results from more than 100 patients
have demonstrated that chloroquine phosphate is superior to the
control treatment in inhibiting the exacerbation of pneumonia,
improving lung imaging findings, promoting a virus negative
conversion, and shortening the disease course", but results
are yet to be published as of 21  April 2020 (Gao 2020). A
small non-randomized study of hospitalized patients in Marseille,
France,  reported that HCQ was associated with earlier negative
nasopharyngeal PCR for SARS-CoV-2 among 20 patients given 200
mg three times per day for 10 days compared to patients not
receiving HCQ (Gautret 2020a). Participants were included if they
had a positive PCR test for SARS-CoV-2, were aged ≥12 years,
had no allergy/contraindication to HCQ, and were not pregnant/
breastfeeding. Of 42 initial participants, 36 were included in the
final analysis: six (all in the HCQ arm) were removed due to loss
to follow-up within three days of enrolment, including three who
were transferred for intensive care and one who died. The 36
participants included eight participants with lower respiratory tract
infection and six participants with asymptomatic disease; most
(22/36) had upper respiratory tract symptoms (Gautret 2020a). The
control group (16 participants) comprised those who had refused to
take HCQ or had presented to other hospitals. Virological clearance
(defined as negative PCR for SARS-CoV-2) at day 6 post-enrolment
was 14/20 (70%) in the HCQ arm, and 2/16 (12.5%) in the group not
receiving HCQ. Subgroup analyses appeared to show a statistically
significant increase in virological clearance for six participants who
had azithromycin in combination with HCQ (Gautret 2020a). The
study authors did not present clinical eGicacy or safety data, and no
eGect estimates nor confidence intervals (CIs) were reported. The
study was also underpowered in terms of sample size.
The presentation of individual patient data in a supplementary
table has allowed further analyses to be conducted (Gautret
2020a). One preprint publication reports re-analysis of the data
using regression and survival models, showing wide CIs for eGect
size estimates   (Lover 2020). The author recommends larger
randomized trials, but interprets the survival model re-analysis
results to show greater promise of the combination of HCQ plus
azithromycin versus neither drug (Lover 2020). Another preprint
applies Bayesian methods to the original data, showing a lack of
robustness to assumptions about participants lost to follow-up and
the four with unfavourable clinical outcomes in the HCQ group
(Hulme 2020). The authors caution against concluding eGicacy of
HCQ or its combination with azithromycin (Hulme 2020).
Following results of the non-randomized study above, the
same research group from France has published a preprint of
an observational single-arm cohort of 80 patients given HCQ
plus azithromycin (Gautret 2020b). They provide limited clinical
outcome data: 65/80 patients showed clinical improvement
(Gautret 2020b). A table in this preprint mentions blurred vision as
an adverse event in one patient aTer five days of treatment, without
further details; this is of concern, due to  HCQ's  association  with
retinopathy (Gautret 2020b).
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Another research group from France advise caution in the use of
this combination of HCQ and azithromycin in their journal preproof
case series, and report much poorer clinical and virological
outcomes in 11 hospitalized patients treated with both drugs
(Molina 2020). Of their patients, 8/11 had co-morbidities and 10/11
were receiving oxygen therapy. Over five days, one patient died,
two were transferred to the intensive care unit, and another patient
had to discontinue therapy due to prolongation of QTc interval on
electrocardiography. Of 10 patients alive at five days, eight had a
positive PCR for SARS-CoV-2 RNA on nasopharyngeal swabs at 5 to
6 days aTer commencing treatment (Molina 2020).
Two small randomized trials of HCQ have reported recently from
China, with mixed results (Chen 2020a; Chen 2020b). Of the trials
underway, some are large multicentre multi-arm RCTs coordinated/
funded by the WHO (ISRCTN83971151), UK National Institute of
Health Research (EudraCT 2020-001113-21), and the US National
Institutes of Health (NCT04280705).
There are currently no studies with human participants reporting
use of CQ or HCQ for prophylaxis of COVID-19. Several trials
exploring use of CQ or HCQ for prophylaxis of COVID-19 are
underway (Cortegiani 2020; Mitjà 2020). Despite lack of data on
prophylaxis, the Indian Council of Medical Research has already
recommended HCQ as pre-exposure prophylaxis for frontline
healthcare workers having “high-risk” contact with patients with
suspected or confirmed COVID-19, and post-exposure prophylaxis
for household and healthcare worker contacts of patients with
confirmed COVID-19 (ICMR 2020). The background section of this
recommendation states there is in vivo evidence for eGicacy of
HCQ for treatment of COVID-19, and prophylactic eGicacy is inferred
from therapeutic eGicacy (ICMR 2020).
Systematic reviews of the evidence for CQ and HCQ in COVID-19
have been produced elsewhere.  A systematic review of CQ for
treatment of COVID-19, which searched PubMed and Embase up
to 1 March 2020, identified no published studies other than the
aforementioned letter (Gao 2020); though 23 clinical trials of CQ or
HCQ were found on registries (Cortegiani 2020)  Another systematic
review of CQ and HCQ for treating COVID-19, published as a preprint
on 30 March 2020, concluded: “There is theoretical, experimental,
preclinical and clinical evidence of the eGectiveness of chloroquine
in patients aGected with COVID-19” (Kapoor 2020). A further review
included one non-randomized study and one randomized trial,
and concluded "Without further evidence, HCQ is not appropriate
for patients with COVID-19 in primary care"  (McCormack 2020).
A systematic review of antimalarials (CQ and HCQ) for treatment
of COVID-19 was produced by the Epistemonikos Working Group.
They synthesized results of two small randomized trials, finding
low to very low certainty evidence regarding eGicacy and harms
(Epistemonikos 2020).
We propose that, in this context, a systematic review using standard
Cochrane methods that provides summary estimates of eGects
for both treatment and prophylactic use of CQ and HCQ, with
an appraisal of the certainty of the evidence using the GRADE
approach,  is important for the general public, clinicians, and
policymakers.   We plan to update this review in an expedited
fashion as new data becomes available from the trials that are
currently in progress.
O B J E C T I V E S
To evaluate the eGects of chloroquine (CQ) and hydroxychloroquine
(HCQ) as:
1. an antiviral treatment on death and time to clearance of the virus
from clinical samples and recovery in people with COVID-19;
2. a prophylactic treatment on prevention of COVID-19 in people at
risk of SARS-CoV-2 exposure;
3. a prophylactic treatment on prevention of COVID-19 in people
who have been exposed to SARS-CoV-2.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Objective 1. People who have COVID-19, as defined by study
authors.
Objective 2. People who are at risk of SARS-CoV-2 exposure, as
defined by study authors.
Objective 3. People who have been exposed to SARS-CoV-2, as
defined by study authors.
Types of interventions
Intervention
Chloroquine (CQ) or hydroxychloroquine (HCQ) given by any route
of administration and dose used alone or in combination with other
treatments.
Control
No treatment, supportive treatment, or other experimental
antiviral treatment.
Types of outcome measures
The outcomes of interest are diGerent for CQ/HCQ used to treat
COVID-19 disease, and for CQ/HCQ used as pre- or post-exposure
prophylaxis to prevent COVID-19 disease.
Objective 1. For treatment of COVID-19 disease
Primary outcomes
• Death
• Time to negative PCR for SARS-CoV-2 on respiratory samples
Secondary outcomes
• Number of participants admitted to hospital (if receiving
ambulatory treatment)
• Number of participants requiring mechanical ventilation
• Length of hospital admission
• Time to clinical improvement, as defined by study authors
• Duration of mechanical ventilation post-enrolment in survivors
of COVID-19
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Objective 2. For prevention of COVID-19 disease in people at risk
of exposure to SARS-CoV-2
Primary outcomes
• Development of confirmed COVID-19, as defined by study
authors
• Production of antibodies to SARS-CoV-2
Secondary outcomes
• Development of COVID-19 in household contacts of the recipient
of the prophylaxis
• Disease severity of participants who develop COVID-19, as
defined by study authors
Objective 3. For prevention of COVID-19 disease in people who
have been exposed to SARS-CoV-2
Primary outcomes
• Development of COVID-19confirmed COVID-19, as defined by
study authors
• Production of antibodies to SARS-CoV-2
Secondary outcomes
• Development of COVID-19 in household contacts of the recipient
of the prophylaxis
• Disease severity of participants who develop COVID-19, as
defined by study authors
Adverse events (relating to objectives 1, 2, and 3)
• All adverse events
• All serious adverse events attributed to study drug (that is,
serious adverse eGects)
• QT-interval prolongation
Search methods for identification of studies
We will attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms
and strategy described in Appendix 1: the Cochrane Central
Register of Controlled Trials (CENTRAL), published in the Cochrane
Library; MEDLINE (PubMed); and Embase (OVID). We will also
search Current Controlled Trials (www.controlled-trials.com) using
'chloroquine', 'hydroxychloroquine', 'coronavirus', and 'COVID-19'
as search terms; and we will search COVID-specific resources
www.covid-nma.com and https://covid-19.cochrane.org/, which
are updated daily with lists of ongoing and published trials.
Searching other resources
We will contact researchers in the field to identify unpublished or
ongoing studies.
Data collection and analysis
For selection of studies and data extraction, two review authors
(BS and HR) will independently conduct each step, and examine
agreement between them. We will resolve any disagreements
through discussion.
Selection of studies
Two review authors (BS and HR or MC) will independently screen
the search results using Covidence (Covidence 2020), and will
retrieve the full-text articles of all potentially relevant trials. We
will examine each trial report to ensure that we include multiple
publications from the same trial only once. We will contact
trial authors for clarification if a trial's eligibility is unclear. We
will resolve any disagreements through discussion, and will list
the excluded studies and the reasons for their exclusion in a
'Characteristics of excluded studies' table. We will illustrate the
study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (BS and HR, MC, or TK) will use a pre-
piloted data extraction form to extract data on participant
characteristics, diagnostic criteria, disease severity, pre-morbid
functional status and co-morbidity, CQ or HCQ dose and
administration, other treatments given, and outcome measures.
We will resolve disagreements through discussion, and will contact
the corresponding trial author in the case of unclear or missing
data.
For dichotomous outcomes, we will record the number of
participants that experienced the event and the number of
participants randomized to each treatment group, and will
use them in the analysis. We will record the number of
participants analysed in each treatment/prophylaxis  arm, and
use the discrepancy between the figures to calculate the number
of participants lost to follow-up, which will allow us to perform
sensitivity analyses to investigate the eGect of missing data.
Assessment of risk of bias in included studies
Two review authors (BS and HR, MC, or TK) will assess
methodological quality using the Cochrane 'Risk of bias' tool and
report the results in a 'Risk of bias' table (Higgins 2011). We will
classify each domain as either at high, low, or unclear risk of bias
(Higgins 2011). We will assess the risk of bias associated with
blinding separately for each outcome; for other domains we will
assess the risk of bias for the trial as a whole. We will attempt
to contact the trial authors if information is not specified or is
unclear. We will resolve any disagreements by discussion between
the review authors.
Measures of treatment e=ect
We will present dichotomous outcomes as risk ratios (RR) and 95%
confidence intervals (CIs). We will report continuous outcomes as
mean diGerences (MD) and 95% CIs if the outcomes have been
measured in the same way across all included trials. In the case that
included trials measured continuous outcomes in diGerent ways,
we will use the standardized mean diGerence (SMDs) and 95% CI
as the eGect measure. We will present time-to-event outcomes as
hazard ratios and 95% CIs.
Unit of analysis issues
We do not anticipate that any cluster-randomized studies will
meet the inclusion criteria of this review. If we identify cluster-
randomized studies that meet the inclusion criteria, we will
ensure appropriate analysis adjusting for the eGect of cluster
randomization is carried out before including eGects estimates in
a meta-analysis. If available, we will extract adjusted measures of
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Protocol)
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eGect from the trial reports. If only unadjusted data are available,
we will adjust this data ourselves using the intracluster correlation
coeGicient (ICC). If the ICC is not reported, we will contact the
study authors to obtain this, or will borrow an ICC value from a
similar study, or will estimate the ICC. If the ICC is estimated, we
will perform sensitivity analyses to investigate the robustness of
our analyses.
If we identify multi-arm trials, we will either select relevant arms for
inclusion in our analyses, or if more than two arms are relevant to
this review, we will either combine intervention arms so that there
is one comparison, or split the control group between multiple
comparisons so that participants are not double-counted in meta-
analysis.
Dealing with missing data
The primary analysis for all outcomes will be an available
case analysis where the denominator is the number of patients
completing follow-up to the point of outcome assessment. We
will carry out sensitivity analyses to explore the impact of missing
data on the primary outcomes. For dichotomous outcomes, we will
vary the event rate within the missing patients from intervention
and control groups within plausible limits. For continuous data we
will also perform sensitivity analyses using methods described by
Ebrahim 2013 and Ebrahim 2014.
Assessment of heterogeneity
We will assess heterogeneity by visually inspecting the forest plots
to determine closeness of point estimates with each other and
overlap of CIs. We used the Chi2 test with a P value of 0.10 to indicate
statistical significance, and the I2 statistic to assess heterogeneity
with a value of 50% taken to indicate statistical heterogeneity.
Assessment of reporting biases
We will construct a funnel plot to investigate any potential reporting
bias if we have 10 or more studies included for an outcome.
Data synthesis
We will analyse the data using Review Manager 5 (RevMan 5)
(Review Manager 2014). In the absence of substantial clinical or
methodological heterogeneity we will perform a meta-analysis,
using risk ratios (RR) with 95% CIs and a random-eGects model.
Where a meta-analysis is not appropriate, we will summarize data
in tables.
Subgroup analysis and investigation of heterogeneity
We plan to investigate heterogeneity by performing the following
subgroup analyses for people with COVID-19:
• Disease severity at presentation
• Time in the illness when treatment started (< 7 days, and ≥ 7
days aTer symptoms started)




• Admitted to hospital  versus  receiving ambulatory/outpatient
treatment
• CQ or HCQ dosing regimen
We plan to investigate heterogeneity by performing the following






• Co-morbidity, such as cardiovascular disease, diabetes, and
immunosuppression
Sensitivity analysis
To explore the possible eGect of losses to follow-up on the eGect
estimates for the primary outcomes, we will perform sensitivity
analyses. For dichotomous outcomes, we will vary the event
rate within the missing patients from intervention and control
groups within plausible limits. For continuous data we will perform
sensitivity analyses using methods described by Ebrahim 2013 and
Ebrahim 2014.
Summary of findings and assessment of the certainty of the
evidence
We will summarize the results of the analysis in  'Summary of
findings' tables for each of the two objectives, and will present
the summary eGects estimates  for the primary outcomes with
illustrative comparative risks. We will use the GRADE framework to
evaluate the certainty of evidence for each outcome, as developed
by the  GRADE Working Group and described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2019).
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A P P E N D I C E S




#2 Search (coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan*
or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19"
or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCoV or "HCoV-19" or HCoV19 or CoV
or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-
CoV2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or
Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*) Field: Title/Abstract
#3 Search (((respiratory* AND (symptom* or disease* or illness* or condition*)) or "seafood market*"
or "food market*") AND (Wuhan* or Hubei* or China* or Chinese* or Huanan*)). Field: Title/Abstract
#4 Search "severe acute respiratory syndrome*" Field: Title/Abstract
#5 Search ((outbreak* or wildlife* or pandemic* or epidemic*) AND (China* or Chinese* or Huanan*))
Field: Title/Abstract
#6 Search (corona* or corono*) AND (virus* or viral* or virinae*) Field: Title/Abstract
#7 Search (((((#1) OR #2) OR #3) OR #4) OR #6)
#8 Search chloroquin* Field: Title/Abstract
#9 Search Hydroxychloroquin* OR Oxychloroquin* Field: Title/Abstract
#10 Search ("Hydroxychloroquine"[Mesh]) OR "Chloroquine"[Mesh]
#11 Search Aralen or Plaquenil Field: Title/Abstract
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#12 Search antimalaria* or anti-malaria* Field: Title/Abstract
#13 Search (((#8) OR #9) OR #10) OR #11OR #12
#14 Search (#13) AND #7
This is the preliminary search strategy for MEDLINE (PubMed). It will adapted for other electronic databases. We will report all search
strategies in full in the final version of the review.
  (Continued)
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